Insider · CIK 0001922939
Thomas Cahill
director
Files at PRME (Prime Medicine, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | PRME Prime Medicine, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -39,062 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +39,062 | - | - | 39,062 | Aug 5, 2025 |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -45,000 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +45,000 | - | - | 45,000 | Aug 5, 2025 |
| Jun 4, 2025 | PRME Prime Medicine, Inc. | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.